{"id":1827,"date":"2024-02-06T12:03:57","date_gmt":"2024-02-06T12:03:57","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?p=1827"},"modified":"2026-01-28T21:43:20","modified_gmt":"2026-01-28T21:43:20","slug":"onl-therapeutics-to-present-at-2024-bio-ceo-investor-conference","status":"publish","type":"post","link":"https:\/\/onltherapeutics.com\/test\/2024\/02\/06\/onl-therapeutics-to-present-at-2024-bio-ceo-investor-conference\/","title":{"rendered":"ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference"},"content":{"rendered":"\n

ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference<\/h3>\n\n\n\n
<\/div>\n\n\n\n

ANN ARBOR, Mich.<\/strong>, February 6, 2024 <\/strong>\u2013 ONL Therapeutics, Inc.<\/a>, a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor Conference on Tuesday, February 27 at 2:30 PM ET. The conference is taking place February 26-27, 2024, at the New York Marriott Marquis in New York City. <\/p>\n\n\n\n

Mr. Esposito will also be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting may do so by contacting ONL\u2019s company contact at the email below. <\/p>\n\n\n\n

About ONL Therapeutics <\/strong><\/p>\n\n\n\n

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, age-related macular degeneration and inherited retinal disease. <\/p>\n\n\n\n

For more information about ONL Therapeutics, please visit www.onltherapeutics.com<\/a>. <\/p>\n\n\n\n

Company Contact<\/strong>: Linda Kemnitz ONL Therapeutics, Inc. lkemnitz@onltherapeutics.com<\/a> <\/p>\n\n\n\n

<\/p>\n\n\n\n

\n
Download Press Release<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference ANN ARBOR, Mich., February 6, 2024 \u2013 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor […]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"blank","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[5,6],"tags":[],"class_list":["post-1827","post","type-post","status-publish","format-standard","hentry","category-news","category-onl-therapeutics-news"],"featured_image_urls_v2":{"full":"","thumbnail":"","medium":"","medium_large":"","large":"","1536x1536":"","2048x2048":"","gform-image-choice-sm":"","gform-image-choice-md":"","gform-image-choice-lg":""},"post_excerpt_stackable_v2":"

ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference ANN ARBOR, Mich., February 6, 2024 \u2013 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor Conference on Tuesday, February 27 at 2:30 PM ET. The conference is taking place February 26-27, 2024, at the New York Marriott Marquis in New York City.  Mr. Esposito will also be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting…<\/p>\n","category_list_v2":"News<\/a>, News Items<\/a>","author_info_v2":{"name":"ONL Therapeutics","url":"https:\/\/onltherapeutics.com\/test\/author\/onl-therapeutics\/"},"comments_num_v2":"0 comments","_links":{"self":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts\/1827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/comments?post=1827"}],"version-history":[{"count":3,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts\/1827\/revisions"}],"predecessor-version":[{"id":1831,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts\/1827\/revisions\/1831"}],"wp:attachment":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/media?parent=1827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/categories?post=1827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/tags?post=1827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}